Compound

D0968 | israpafant

Molecular Formula C28H29ClN4S
Molecular Weight 489.1
Structure

Toxicity Dose Time Species Model Method Action Positive criterion Reference
MEMBRANE POTENTIAL 21.96±1.49 human qHTS-HepG2 MMP assay decrease IC50 163
MEMBRANE POTENTIAL 27.48 human HepG2 MMP assay decrease IC50 163
MEMBRANE POTENTIAL 23.46±5.67 rat hepatocytes MMP assay decrease IC50 163


  • (+-)-4-(2-chlorophenyl)-2-[2-(4-isobutylphenyl)ethyl]-6,9-dimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine (+-)-4-(o-Chlorophenyl)-2-(p-isobutylphenethyl)-6,9-dimethyl-6H-thieno(3,2-f)-s-triazolo(4,3-a)(1,4)diazepine (+/-)-israpafant
    117279-73-9 4-(2-Chlorophenyl)-2-(2-(4-isobutylphenyl)ethyl)-6,9-dimethyl-6H-thieno(3,2-f)(1,2,4)triazolo(4,3-a)(1,4)diazepine 4-(2-chlorophenyl)-2-(4-isobutylphenethyl)-6,9-dimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine
    4-(2-chlorophenyl)-2-[2 -(4-isobutylphenyl)ethyl]-6,9-dimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine 4-(2-chlorophenyl)-6,9-dimethyl-2-{2-[4-(2-methylpropyl)phenyl]ethyl}-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine 6H-Thieno(3,2-f)(1,2,4)triazolo(4,3-a)(1,4)diazepine, 4-(2-chlorophenyl)-6,9-dimethyl-2-(2-(4-(2-methylpropyl)phenyl)ethyl)-
    6H-Thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine, 4-(2-chlorophenyl)-6,9-dimethyl-2-[2-[4-(2-methylpropyl)phenyl]ethyl]- 7-(2-chlorophenyl)-9,13-dimethyl-4-{2-[4-(2-methylpropyl)phenyl]ethyl}-3-thia-1,8,11,12-tetraazatricyclo[8.3.0.0^{2,6}]trideca-2(6),4,7,10,12-pentaene; CAS-117279-73-9
    CHEMBL2107428 DSSTox_CID_312 DSSTox_GSID_20312
    DSSTox_RID_75507 DTXSID5020312 GTPL1857
    Israpafant Israpafant [INN] L000999
    LS-185098 NCGC00183008-01 Pafnol
    Q27881903 RMSWMRJVUJSDGN-UHFFFAOYSA-N SCHEMBL121588
    Tox21_113300 Y 24180 Y-24180

    CAS Number 117279-73-9
    PubChem Compound 119175
    KEGG Drug D02590
    ChEBI 31736